Loading
MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer and Diffuse large B-cell lymphoma.
Protease that enhances BCL10-induced activation: acts via formation of CBM complexes that channel adaptive and innate immune signalling downstream of CARD domain-containing proteins (CARD9, CARD11 and CARD14) to activate NF-kappa-B and MAP kinase p38 pathways which stimulate expression of genes encoding pro-inflammatory cytokines and chemokines. Mediates BCL10 cleavage: MALT1-dependent BCL10 cleavage plays an important role in T-cell antigen receptor-induced integrin adhesion. Involved in the induction of T helper 17 cells (Th17) differentiation.
Open Targets scores its association with cancer at 0.62 (direct and indirect evidence; datatypes literature 0.97, genetic association 0.04, somatic mutation 0.97). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS.
In plain words · MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer and Diffuse large B-cell lymphoma.
MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer and Diffuse large B-cell lymphoma.
Protease that enhances BCL10-induced activation: acts via formation of CBM complexes that channel adaptive and innate immune signalling downstream of CARD domain-containing proteins (CARD9, CARD11 and CARD14) to activate NF-kappa-B and MAP kinase p38 pathways which stimulate expression of genes encoding pro-inflammatory cytokines and chemokines.
No product in this corpus aims at MALT1 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
First described 1999. Earliest sequence paper UniProt cites for the protein: Dierlamm et al, Blood, 1999, "The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas". Source.
Sources: HGNC HGNC:6819 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9UDY8 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000172175 (association with cancer (MONDO_0004992) 0.62; per-cancer scores at or above 0.5: skin cancer 0.51 (GraphQL API, CC0)); IntOGen MALT1 (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Protease that enhances BCL10-induced activation: acts via formation of CBM complexes that channel adaptive and innate immune signalling downstream of CARD domain-containing proteins (CARD9, CARD11 and CARD14) to activate NF-kappa-B and MAP kinase p38 pathways which stimulate expression of genes encoding pro-inflammatory cytokines and chemokines. Mediates BCL10 cleavage: MALT1-dependent BCL10 cleavage plays an important role in T-cell antigen receptor-induced integrin adhesion. Involved in the induction of T helper 17 cells (Th17) differentiation. Cleaves RC3H1 and ZC3H12A in response to T-cell receptor (TCR) stimulation which releases their cooperatively repressed targets to promote Th17 cell differentiation. Also mediates cleavage of N4BP1 in T-cells following TCR-mediated activation, leading to N4BP1 inactivation. May also have ubiquitin ligase activity: binds to TRAF6, inducing TRAF6 oligomerisation and activation of its ligase activity. Location: Cytoplasm, perinuclear region; Nucleus (UniProt). Locus 18q21.32 (HGNC).
Query for this target: (TITLE:"MALT1" OR ABSTRACT:"MALT1" OR TITLE:"MALT1 paracaspase" OR ABSTRACT:"MALT1 paracaspase" OR TITLE:"Mucosa-associated lymphoid tissue lymphoma translocation protein 1" OR ABSTRACT:"Mucosa-associated lymphoid tissue lymphoma translocation protein 1" OR TITLE:"PCASP1" OR ABSTRACT:"PCASP1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MALT1, not a curated reading list.
Shares Microbiome-tumour interactions, B-cell receptor / BTK signalling (to NF-κB), Inflammation & NF-κB, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma).
Shares Microbiome-tumour interactions, Inflammation & NF-κB, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Marginal zone lymphoma.
Shares Microbiome-tumour interactions, Inflammation & NF-κB, Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Marginal zone lymphoma.
Shares B-cell receptor / BTK signalling (to NF-κB), Inflammation & NF-κB, Skin cancer (all types), IntOGen.
Shares B-cell receptor / BTK signalling (to NF-κB), Inflammation & NF-κB, IntOGen, Diffuse large B-cell lymphoma.
Shares Marginal zone lymphoma, Skin cancer (all types), IntOGen, Diffuse large B-cell lymphoma.
Shares B-cell receptor / BTK signalling (to NF-κB), IntOGen, Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types).
Shares B-cell receptor / BTK signalling (to NF-κB), Inflammation & NF-κB, Skin cancer (all types), Non-Hodgkin lymphoma (all types).